Genmab A/S (GMAB) Reports Q2 Net Sales of DARZALEX of $1.97B

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 1,986 million in the second quarter of 2022. Net trade sales were USD 1,021 million in the U.S. and USD 965 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• cBrain wins first California state contract for AI permitting tool